Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.54 |
| ▸ | GSR | P00390 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Citrulline SCHEMBL20588 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL288641 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20587 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL9070200 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL437142 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL15909605 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL4542892 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL15909604 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL22426116 | 1.00 | OTC (0.59) | OTCDDAH1GSRNOS2CYP1A2 | |
| L-Citrulline SCHEMBL20742804 | 0.98 | OTC (0.57) | OTCDDAH1GSRNOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3269737-B1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4374879-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| EP-4332117-A1 | ANTI-NECTIN-4 ANTIBODY AND ANTI-NECTIN-4 ANTIBODY-DRUG CONJUGATE, AND MEDICINAL USER THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20240026028-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230405138-A1 | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| EP-4230653-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-4190812-A1 | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2007109567-A1 | ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1812465-A1 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | Genentech, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1786838-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006054961-A2 | NOVEL COMPOSITION AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | GENENTECH, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006029183-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20050272118-A1 | Novel composition and methods for the treatment of immune related diseases | GENENTECH, INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050107595-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050106644-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | disclosed |
| US-5541159-A | PEPTIDE HORMONE ANTAGONIST | SANDOZ LTD. (CH) | 1996-07-30 | — | — | US | disclosed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405138-A1 | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | CD79B, CD99, MMAB | OTC 3278/4885DDAH1 2784/4885GSR 4479/4885 |
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | FOLH1, ENPEP, PEPD | OTC 4069/4885DDAH1 4052/4885GSR 4648/4885 |
| US-20240026028-A1 | ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF | ERBB3, EGFR, ERBB2 | OTC 4186/4885DDAH1 1849/4885GSR 4538/4885 |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | OTC 4323/4885DDAH1 1445/4885GSR 4554/4885 |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | ERLIN1, ERLIN2, EZR | OTC 3650/4885DDAH1 2812/4885GSR 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.